Clostridium perfringens epsilon toxin (ETX) (ETX)

Clostridium perfringens epsilon toxin (ETX) is a highly potent pore-forming exotoxin produced by C. perfringens types B and D, and it is the causative agent of fatal enterotoxemia in ruminants (PubMed: 25135378). The toxin is secreted as a relatively inactive protoxin that is activated by host proteases in the gastrointestinal tract, after which it enters the bloodstream and targets the blood-brain barrier and kidneys (Merck Veterinary Manual). ETX exerts its toxicity by binding to the myelin and lymphocyte protein (MAL) on host cells, leading to heptameric pore formation and rapid cytolysis (PubMed: 24558148). In veterinary medicine, the "toxoid" form—a formaldehyde-inactivated version of the toxin—is used as a vaccine to stimulate the production of neutralizing antibodies that prevent the active toxin from binding to its receptors (PubMed: 15501278). While primarily a veterinary concern, ETX has gained attention in human medicine due to its potential role as an environmental trigger for multiple sclerosis, as it can specifically target the CNS endothelium and oligodendrocytes (PubMed: 24053343). Therapeutic strategies focus on neutralizing the toxin via vaccination or the development of monoclonal antibodies to prevent systemic damage.

Other names

Clostridium perfringens Type D toxoidEpsilon toxinETXClostridium perfringens epsilon toxoidInactivated epsilon toxin

Vaccines containing the toxoid induce the production of specific IgG antibodies that bind to the epsilon toxin, sterically hindering its ability to bind to the host MAL receptor and preventing the subsequent formation of cytotoxic pores (PubMed: 15501278, PubMed: 24558148).